AstraZeneca Gets EU Approval For Targeted Breast Cancer Therapies

June 27, 2022

AstraZeneca (AZN.L) said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio.

Lynparza, a cancer drug developed jointly with U.S.-based Merck (MRK.N), was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.

The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies.

Enhertu, developed jointly with Japan's Daiichi Sankyo (4568.T), was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

Enhertu is seen as a major growth driver for AstraZeneca, with some analysts expecting peaks sales of $10 billion. The drug is also expected to be cleared for patients with low levels of HER2 this month after the recent success of a trial.

SOURCE: REUTERS
IMAGE SOURCE: PIXABAY

THE METRO BUSINESS

The Education That Matters: MSBM’s Guide to Thinking, Thriving, and Leading

How MSBM’s Executive Courses Prepare You to Out-think and Outperform the Competition

Jailed US Reporter Gershkovich, to Stand Trial in Russia on Espionage Charges

Tesla to raise Model 3 prices in Europe after higher EU tariffs on China EVs

AstraZeneca Gets EU Approval For Targeted Breast Cancer Therapies

Top Stories

Insider Tips for Excelling in MSBM’s Online Courses

Strategies for Success: MSBM’s Business Management Insights

Nations are vying to join the BRICS group, according to South Africa, as Russia assumes leadership.

Home Secretary vows to reduce net migration.

Related Posts

Skin Cancer Death Are Higher For Men Than Women: Sunburns Can Triple Your Risk Of Skin Cancer

Fake Charities: Here’s How To Avoid Scam Charities And Safeguard Your Donations

Covid Vaccine: After Taking The Vaccines, Noticed ‘Waning Immunity’: How Worried Should I Be?

UK Strikes Escalate In Run-Up To Christmas As Workers Fight For Salary Hikes